Sihuan Pharmaceutical Holdings Group (SHPHF) Stock Price & Analysis

9 Followers

SHPHF Stock Chart & Stats

$0.12$0.00(0.00%)

At close: Nov 11 4:00 PM EST

Day’s Range: $0.12 - $0.12
52-Week Range: $0.10 - $0.21
Previous Close: $0.12
Volume: N/A
Average Volume (3M): 0
Market Cap: $969.38M
Enterprise Value: $6.90B
Total Cash (Recent Filing): $3.72B
Total Debt (Recent Filing): $969.22M
Price to Earnings (P/E): 20.5
Beta: 0.50
Next Earnings: Apr 01, 2027 (Est.)
EPS Estimate: N/A
Last Dividend Ex-Date: Jul 02, 2026
Dividend Yield: 1.16%

Bulls Say, Bears Say

Bulls Say

Revenue Recovery

The sharp 2025 revenue rebound and return to profitability indicate renewed commercial traction after two loss-making years. If this recovery persists, greater scale can support investment in the company’s prescription portfolio, distribution network, and future earnings capacity.

High Gross Margins

Sustained gross margins near 65–70% provide a meaningful economic buffer and show that the company’s products retain substantial value after production costs. This margin structure can support operating investment and earnings leverage as revenue expands, provided profitability remains stable.

Manageable Leverage

Falling debt-to-equity indicates reduced balance-sheet pressure and leaves the company with greater financial flexibility through business volatility. A sizable equity base relative to debt also provides a cushion for maintaining operations and funding strategic priorities while earnings recover.

Bears Say

Weak Cash Generation

Negative operating and free cash flow alongside positive reported earnings is an unfavorable quality-of-earnings signal. If sustained, cash conversion could constrain internal funding, reduce flexibility for product investment, and increase reliance on balance-sheet resources to support growth.

Earnings Volatility

The recent earnings history shows that profitability has not yet demonstrated consistent durability across the cycle. Large swings in results make forward earnings capacity less predictable and could limit management’s ability to plan investment, capital allocation, and shareholder returns confidently.

Low Return On Equity

The modest 2025 ROE shows that the company’s sizable equity base is not yet producing consistently strong shareholder returns. Persistently low or negative returns would weaken the compounding potential of the business and indicate that balance-sheet strength is not translating efficiently into profits.

Sihuan Pharmaceutical Holdings Group News

Sihuan’s Anaprazole Shows Strong Phase III Results in Reflux Esophagitis

Sihuan Pharmaceutical Holdings Group ( ($HK:0460) ) just unveiled an announcement. Sihuan Pharmaceutical’s subsidiary Xuanzhu Biopharm reported Phase III trial data for Anaprazole Sodium in moderate-to-severe reflux esophagitis, showing non-inferiority

3w agoSHPHF TEL1

Sihuan Pharmaceutical Wins Hong Kong Approval for Key Medical Aesthetic Products

Sihuan Pharmaceutical Holdings Group ( ($HK:0460) ) has shared an announcement. Sihuan Pharmaceutical’s subsidiary Meiyan Space has secured approval in Hong Kong for its self-developed Polycaprolactone Microsphere Facial Filler for

3w agoSHPHF TEL1

Sihuan Pharmaceutical Invests in Canton Biologics to Build Full-Chain Regenerative Aesthetics Platform

An update from Sihuan Pharmaceutical Holdings Group ( ($HK:0460) ) is now available. Sihuan Pharmaceutical, via its subsidiary Meiyan Space Biotechnology, has completed a strategic equity investment in Guangzhou Canton

1M agoSHPHF TEL1

Sihuan Pharmaceutical Expands Dongyan Skin Booster Dosage Range to Strengthen Aesthetics Portfolio

Sihuan Pharmaceutical Holdings Group ( ($HK:0460) ) has issued an announcement. Sihuan Pharmaceutical’s subsidiary Meiyan Space has received Chinese regulatory approval for five new dosage specifications of its Dongyan hyaluronic

1M agoSHPHF TEL1

Sihuan’s Xuanzhu Biopharm Strikes Exclusive Bireociclib Deal in Thailand

Sihuan Pharmaceutical Holdings Group ( ($HK:0460) ) has issued an announcement. Sihuan Pharmaceutical’s non-wholly owned subsidiary Xuanzhu Biopharm has signed a tri-party commercial agreement with Thailand’s Innobic (Asia) and ZaoAn

2M agoSHPHF TEL1

Sihuan Pharmaceutical Grants 116 Million Performance-Based Share Awards

Sihuan Pharmaceutical Holdings Group ( ($HK:0460) ) just unveiled an announcement. Sihuan Pharmaceutical Holdings Group has granted 116,150,000 share awards under its 2026 Share Incentive Scheme, equivalent to about 1.27%

2M agoSHPHF TEL1

Sihuan Pharma Launches Share Buyback as Profit Surges on Aesthetics Push

Sihuan Pharmaceutical Holdings Group ( ($HK:0460) ) has shared an update. Sihuan Pharmaceutical Holdings Group has stepped up its capital management by repurchasing 10 million shares on the open market

2M agoSHPHF TEL1

Sihuan Pharmaceutical Reshapes Leadership With CFO Exit and New Non-Executive Director

Sihuan Pharmaceutical Holdings Group ( ($HK:0460) ) has shared an announcement. Sihuan Pharmaceutical announced that Ms. Miao Guili has resigned as executive director, deputy chief executive officer and chief financial

2M agoSHPHF TEL1

Sihuan Pharmaceutical Clarifies Board and Committee Structure

Sihuan Pharmaceutical Holdings Group ( ($HK:0460) ) has issued an announcement. Sihuan Pharmaceutical Holdings Group Ltd. has announced the current composition of its board of directors, detailing the roles of

2M agoSHPHF TEL1

Sihuan Pharmaceutical Leans on Aesthetics and Innovation as Generic Drug Margins Erode

Sihuan Pharmaceutical Holdings Group ( ($HK:0460) ) has shared an announcement. Sihuan Pharmaceutical reported interim revenue of RMB1,161.2 million for the six months ended 30 June 2026, up 1.3% year

2M agoSHPHF TEL1

SHPHF FAQ

What was Sihuan Pharmaceutical Holdings Group’s price range in the past 12 months?

Sihuan Pharmaceutical Holdings Group lowest stock price was $0.10 and its highest was $0.21 in the past 12 months.

What is Sihuan Pharmaceutical Holdings Group’s market cap?

Sihuan Pharmaceutical Holdings Group’s market cap is $969.38M.

When is Sihuan Pharmaceutical Holdings Group’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Sihuan Pharmaceutical Holdings Group’s earnings last quarter?

Sihuan Pharmaceutical Holdings Group released its earnings results on Aug 26, 2026. The company reported $0.004 earnings per share for the quarter.

Is Sihuan Pharmaceutical Holdings Group overvalued?

According to Wall Street analysts Sihuan Pharmaceutical Holdings Group’s price is currently Undervalued.

Does Sihuan Pharmaceutical Holdings Group pay dividends?

Sihuan Pharmaceutical Holdings Group pays an annual dividend of $0.001 which represents an annual dividend yield of 1.16%. See more information on Sihuan Pharmaceutical Holdings Group dividends here

What is Sihuan Pharmaceutical Holdings Group’s EPS estimate?

Sihuan Pharmaceutical Holdings Group’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Sihuan Pharmaceutical Holdings Group have?

Sihuan Pharmaceutical Holdings Group has 9,329,999,000 shares outstanding.

What happened to Sihuan Pharmaceutical Holdings Group’s price movement after its last earnings report?

Sihuan Pharmaceutical Holdings Group reported an EPS of $0.004 in its last earnings report. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Sihuan Pharmaceutical Holdings Group?

Currently, no hedge funds are holding shares in SHPHF

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description